The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis
NCT05326906
·
clinicaltrials.gov ↗
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
PD-1/PD-L1 inhibitors
Sponsor
Hunan Province Tumor Hospital